Related Experiment Video

Updated: Apr 24, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

Reduced fibrinogen, fibrinolytic biomarkers, and physical parameters after a weight-loss program in obese subjects

Che Badariah Abdul Aziz1, Norsuhana Omar1, Wan Zaidah Abdullah2

  • 1Department of Physiology, School of Medical Sciences, Kelantan, Malaysia.

North American Journal of Medical Sciences
|September 12, 2014
PubMed

Insights

A 12-week weight-loss program significantly reduced fibrinogen and fibrinolytic markers in obese individuals. This intervention improved key hemostatic parameters, suggesting benefits for cardiovascular health.

Area of Science:

  • Obesity research
  • Cardiovascular health
  • Hemostasis and thrombosis

Background:

  • Obesity is linked to increased risk of stroke and coronary heart disease (CHD).
  • Disturbances in the hemostatic system contribute to these comorbidities in obese individuals.

Purpose of the Study:

  • To investigate the impact of a structured weight-loss program on fibrinogen and fibrinolytic markers.
  • To assess changes in key hemostatic factors following a 12-week intervention.

Main Methods:

  • Twenty-eight obese participants underwent a 12-week program combining exercise and nutritional education.
  • Blood samples were analyzed pre- and post-intervention for fibrinogen, tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI).

Main Results:

  • Significant reductions were observed in fibrinogen, t-PA, PAI-1, and TAFI levels post-intervention (P < 0.01).
  • Positive correlations were found between tPA levels and body weight, BMI, waist circumference, and fat-free mass.
  • BMI also showed significant correlations with other measured blood parameters.

Conclusions:

  • The weight-loss program effectively reduced fibrinogen and fibrinolytic markers in obese subjects.
  • These findings indicate potential beneficial effects of weight reduction on the hemostatic system, particularly fibrinolytic biomarkers.
Abstract

Keywords:
ExerciseFibrinogenObesePlasminogen activatorPlasminogen activator inhibitor-1Thrombin activatable fibrinolysis inhibitor

More Related Videos

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads07:59

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

9.2K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

732

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
634
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
431
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
319
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
361
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K